← Back to Patent Explorer
US4066510A Expired / Lapsed US ⏱️ 0.0 years remaining

Assay for mutagenesis in diploid human lymphoblasts

Assignee: Massachusetts Institute of Technology
•
Filing: 1976-05-24
•
Granted: 1978-01-03
•
Expires: 1996-05-24
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract An assay is disclosed for determining mutagenic damage caused by the administration of a known or suspected mutagen to diploid human lymphoblastoid cell lines. After administration of or exposure to a mutagenic agent, the lymphoblasts are incubated for a sufficient number of generations to allow full expression of phenotypic resistance to 6-thioguanine or other purines which serve as substrates for hypoxanthine guanine phosphoribosyl transferase (HGPRT). A surprising discovery is the remarkably long length of time required for such phenotypic expression. After the phenotypic lag has passed, the mutant fraction can be determined to complete the assay. A nontoxic, active, sterile microsomal drug-metabolizing system compatible with mammalian cell bioassays is also disclosed which can be used in the assay to determine metabolite-caused mutagenesis. These bioassay systems can be used by genetic toxicologists to determine the potential genetic hazards to human beings for a variety of suspected or known mutagens, including newly developed chemicals.

Inventors

  • 👤 William G. Thilly

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 05:57
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5008; G01N33/5014; G01N33/5017

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 89 words
An assay for determining mutagenesis, comprising: a. exposing a culture of human diploid or near-diploid cells capable of continuous division in suspension culture and having one active x-chromosome which carries the gene for HGPRT to an agent to be tested for its mutagenic effects on said cells; b. incubating exposed cells for a number of generations sufficient to allow full expression of phenotypically-developed resistance to a purine which acts as an HGPRT substrate; and then, c. detecting the amount of mutant cells to thereby determine the degree of mutagenesis.
Claim 2
Dependent Claim 89 words
An assay for determining mutagenesis, comprising: a. exposing a culture of human diploid or near-diploid cells capable of continuous division in suspension culture and having one active x-chromosome which carries the gene for HGPRT to an agent to be tested for its mutagenic effects on said cells; b. incubating exposed cells for a number of generations sufficient to allow full expression of phenotypically-developed resistance to a purine which acts as an HGPRT substrate; and then, c. detecting the amount of mutant cells to thereby determine the degree of mutagenesis.
Claim 3
Dependent Claim 10 words
The assay of claim 1 wherein said purine is 6-thioguanine.
Claim 4
Dependent Claim 12 words
The assay of claim 1 wherein said cells comprise human diploid lymphoblasts.
Claim 5
Dependent Claim 10 words
The assay of claim 3 wherein said purine is 6-thioguanine.
Claim 6
Dependent Claim 16 words
The assay of claim 1 wherein an active, drug-metabolizing system is added to the cell cultures.
Claim 7
Dependent Claim 16 words
The assay of claim 4 wherein an active, drug-metabolizing system is added to the cell cultures.
Claim 8
Dependent Claim 33 words
The assay of claim 6 wherein said active, drug-metabolizing system comprises a post-mitochondrial supernatant of homogenized mammalian tissue in an aqueous suspension medium, said post-mitochondrial supernatant having been filtered to remove contaminating bacteria.
Claim 9
Dependent Claim 12 words
The assay of claim 7 wherein said drug-metabolizing system also contains NADH.
Claim 10
Dependent Claim 75 words
The assay for determining mutagenesis comprising: a. exposing a culture of a human, diploid, lymphoblastoid cell line to an agent to be tested under conditions whereby at least some of the cells survive; b. resuspending exposed cells in fresh medium; c. incubating the resuspended, exposed cells for a sufficient number of generations to allow the expression of the substantially fully phenotypically-developed cell resistance to a purine HGPRT substrate; and, d. determining the induced mutant fraction.
Claim 11
Dependent Claim 75 words
The assay for determining mutagenesis comprising: a. exposing a culture of a human, diploid, lymphoblastoid cell line to an agent to be tested under conditions whereby at least some of the cells survive; b. resuspending exposed cells in fresh medium; c. incubating the resuspended, exposed cells for a sufficient number of generations to allow the expression of the substantially fully phenotypically-developed cell resistance to a purine HGPRT substrate; and, d. determining the induced mutant fraction.
Claim 12
Dependent Claim 12 words
The assay of claim 9 wherein said purine HGPRT substrate is 6-thioguanine.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-01-02 1981-07-04 1982-01-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-01-02 1985-07-04 1986-01-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-01-02 1989-07-04 1990-01-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag